Reuters: Regulatory News: Exact Sciences test detects 92 pct colorectal cancers

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

Exact Sciences test detects 92 pct colorectal cancers Apr 18th 2013, 10:56 April 18 | Thu Apr 18, 2013 6:56am EDT April 18 (Reuters) - Exact Sciences Corp said its molecular screening test for colorectal cancer met the main goal of detecting the disease in more patients than other commonly used screening tests in a large late-stage study. Exact's test, which identifies abnormal DNA in cells shed in a patient's stool, detected 92 percent of colorectal cancers and 42 percent of pre-cancerous polyps in a study on more than 10,000 people, the company said on Thursday. The study compared the performance of the Cologuard test to colonoscopy and fecal immunochemical testing or FIT.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions